Individually Tailored Cannabis Extracts Improved Pain and Quality of Life in 29 Women

In a retrospective study of 29 women with chronic pain syndromes, individually dosed full-spectrum cannabis extracts provided pain relief, improved cognition and sleep, and most reduced or stopped other medications.

Soares Silva, Patrícia Montagner et al.·Frontiers in pharmacology·2025·Preliminary EvidenceObservational
RTHC-07688ObservationalPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
Preliminary Evidence
Sample
N=29

What This Study Found

All 29 patients reported some pain relief. Most reported improvements in cognitive function, motor abilities, professional activities, irritability, anxiety, fatigue, and sleep quality. Most reduced or ceased analgesic and psychiatric medications. No patients discontinued due to adverse effects. Optimal CBD-to-THC proportions varied considerably with no clear link to pain types.

Key Numbers

29 female patients. All reported some pain relief. Most improved across cognitive, motor, mood, fatigue, and sleep domains. Most reduced or stopped analgesic and psychiatric medications. Zero discontinuations due to adverse effects. Optimal dosing varied considerably across patients.

How They Did This

Retrospective open-label cross-sectional study of 29 female chronic pain patients who received full-spectrum cannabis extracts with standardized compositions from patient-led civil societies. Individually tailored dosing based on clinical assessments. Outcomes via comprehensive online patient-reported survey.

Why This Research Matters

Women experience chronic pain differently due to sex-specific differences in pain perception and cannabinoid pharmacology. This study focuses specifically on female patients with individually tailored dosing, an approach that may be more realistic than fixed-dose trials.

The Bigger Picture

While this study suggests individualized dosing may be key to cannabis treatment success, the lack of a control group and retrospective design mean improvements could reflect placebo effects, natural fluctuation, or the extra attention from individualized care.

What This Study Doesn't Tell Us

No control group. Retrospective self-report. Only 29 patients. Patient-led civil society sourced products. Self-selected participants likely biased toward positive experiences. No standardized outcome measures.

Questions This Raises

  • ?What determines the optimal CBD-to-THC ratio for individual patients?
  • ?Would a controlled trial replicate these broad improvements?

Trust & Context

Key Stat:
Evidence Grade:
Retrospective, uncontrolled study with self-selected patients and patient-reported outcomes only places this at preliminary evidence.
Study Age:
Recently published retrospective report.
Original Title:
Full-spectrum cannabis extracts for women with chronic pain syndromes: a real-life retrospective report of multi-symptomatic benefits after treatment with individually tailored dosage schemes.
Published In:
Frontiers in pharmacology, 16, 1538518 (2025)
Database ID:
RTHC-07688

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

Does cannabis work the same for all types of chronic pain?

The study found no clear link between optimal CBD-to-THC proportions and specific pain types, suggesting that individual response varies regardless of pain diagnosis.

Did patients stop their other medications?

Most reduced or ceased analgesic and psychiatric medications while using cannabis extracts, though this was done under clinical supervision with individualized dosing adjustments.

Read More on RethinkTHC

Cite This Study

RTHC-07688·https://rethinkthc.com/research/RTHC-07688

APA

Soares Silva, Patrícia Montagner; Medeiros, Wesley; Nogueira Borges, Clarissa; Brasil-Neto, Joaquim P; Lessa, Wilson; Ferreira de Oliveira E Silva, Ricardo; Caixeta, Fabio V; Malcher-Lopes, Renato. (2025). Full-spectrum cannabis extracts for women with chronic pain syndromes: a real-life retrospective report of multi-symptomatic benefits after treatment with individually tailored dosage schemes.. Frontiers in pharmacology, 16, 1538518. https://doi.org/10.3389/fphar.2025.1538518

MLA

Soares Silva, Patrícia Montagner, et al. "Full-spectrum cannabis extracts for women with chronic pain syndromes: a real-life retrospective report of multi-symptomatic benefits after treatment with individually tailored dosage schemes.." Frontiers in pharmacology, 2025. https://doi.org/10.3389/fphar.2025.1538518

RethinkTHC

RethinkTHC Research Database. "Full-spectrum cannabis extracts for women with chronic pain ..." RTHC-07688. Retrieved from https://rethinkthc.com/research/soares-2025-fullspectrum-cannabis-extracts-for

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.